Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 B'/C Candidate Vaccine
Figure 3
Graphs depict the anti-vaccinia binding antibody titer after each vaccination (arrows) by dose group, expressed as geometric mean titer.
Error bars represent SEM. Arrows indicate vaccination time points. As predicted, anti-vaccinia antibody titers increased after each vaccination and with increasing doses of ADMVA.